The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron works in adult female participants with stress urinary incontinence (SUI) who have obesity or overweight. SUI is leaking urine during movement or activity such as coughing or exercising. Participation in the study will last about 58 weeks from screening to safety follow-up.
Have a body mass index (BMI) of 27 kilograms per square meter (kg/m2) or higher at screening
Have a diagnosis of stress urinary incontinence
Have had urinary incontinence surgery
Have recently received onabotulinumtoxin A (Botox) bladder injections or currently taking medications for urinary incontinence
Have given birth within one year of screening
Have had a change in body weight of more than 11 pounds within 90 days prior to screening
Eli Lilly and Company
Lead sponsor